{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:40:33Z","timestamp":1792683633308,"version":"4.5.0"},"reference-count":0,"publisher":"The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS","issue":"5","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Turkish Journal of Medical Sciences"],"abstract":"<jats:p>AbstractAim: Rheumatoid factor (RF) and Anti Citrullinated Peptide (anti-CCP) is specific for rheumatoid arthritis (RA) diagnosis. However they could be positive in other disease and even healthy populations. It was aimed to investigate the prevalence of positive RF and anti-CCP antibodies in persons admitted to hospital for any reason and on a national scale.Material and Method: The National Electronic Health Database, which contains the clinical records of over eighty million people, is used to design this multi-center, retrospective cohort study. The subjects included in the study were divided into age groups in 10-year periods. RA cases were identified by using ICD-10 codes that included M05,M06, M08,and their subgroups. RF and anti-CCP positivity were evaluated in terms of their contribution to the risk of being diagnosed with RA, with the change according to age and genderResults: During the 1.1.2018-31.12.2021 period, 13.918.072 RF tests were performed in 11.849.440 people, whereas 1.183.607 anti-CCP test were performed in 1.020.967 people. 797.089 people had at least once both tests performed. RF positivity rate in patients who only requested RF test was 14.72% and it was 35.04% for anti-CCP positivity in only requested anti-CCP tests. The rate of concomitant RF and anti-CCP positivity was 22.56%.RA diagnosis is made in in 27.8% of RF-positive people, in 39.73% of anti-CCP-positive people and in %56.6 of co RF and anti CCP positive people. RF positivity and concomitant RF and anti-CCP positivity increased with the age and more common in females.Conclusion: RF and anti-CCP positivity could be seen in a healthy population with female predominance. As the age increases, the risk of RF positivity is increased, however anti \u2013CCP positivity does not change. Concomitant RF and anti-CCP positivity has the highest risk of RA development with respect to either antibody positivity alone.<\/jats:p>","DOI":"10.55730\/1300-0144.5872","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T04:14:36Z","timestamp":1729656876000},"page":"949-955","source":"Crossref","is-referenced-by-count":2,"title":["A nationwide study: prevalence of rheumatoid factor and anti- citrullinated peptide positivity and their contribution to rheumatoid arthritis diagnosis"],"prefix":"10.55730","volume":"54","author":[{"given":"HASAN","family":"SATI\u015e","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ABDULSAMET","family":"ERDEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EMRE","family":"B\u0130LG\u0130N","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u0130ZEM","family":"AYAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BERKAN","family":"ARMA\u011eAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DUYGU","family":"TECER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALPER","family":"SARI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"UMUT","family":"KALYONCU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MURAT","family":"\u00c7A\u011eLAYAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MUSTAFA MAH\u0130R","family":"\u00dcLG\u00dc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MUSTAFA OKAN","family":"AYVALI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NA\u0130M","family":"ATA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eUAY\u0130P","family":"B\u0130R\u0130NC\u0130","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"34691","published-online":{"date-parts":[[2024,10,18]]},"container-title":["Turkish Journal of Medical Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:50:09Z","timestamp":1792680609000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.tubitak.gov.tr\/medical\/vol54\/iss5\/11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":0,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,10,18]]}},"URL":"https:\/\/doi.org\/10.55730\/1300-0144.5872","relation":{},"ISSN":["1300-0144"],"issn-type":[{"value":"1300-0144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]}}}